FASN and neoplasm: More importantly, the combined metabolic-targeting strategy demonstrates potential clinical value: the co-treatment of miR-532-5p and the FASN inhibitor Orlistat significantly suppressed tumor growth and LNM in vivo (18) (as shown in Figure 5).